A Study to Evaluate the Safety, Tolerance, Pharmacokinetics, and Preliminary Antineoplastic Activity of AK132 in Advanced Malignant Solid Tumor
NCT06166472
·
clinicaltrials.gov ↗
PHASE1
Phase
NOT_YET_RECRUITING
Status
72
Enrollment
INDUSTRY
Sponsor class
Conditions
Advanced Malignant Solid Tumor
Interventions
DRUG:
AK132
Sponsor
Akeso